WallStSmart

Cardinal Health Inc (CAH)vsNebius Group N.V. (NBIS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cardinal Health Inc generates 46082% more annual revenue ($244.67B vs $529.80M). NBIS leads profitability with a 19.2% profit margin vs 0.7%. NBIS appears more attractively valued with a PEG of 0.63. CAH earns a higher WallStSmart Score of 53/100 (C-).

CAH

Buy

53

out of 100

Grade: C-

Growth: 7.3Profit: 4.5Value: 8.7Quality: 5.8
Piotroski: 4/9Altman Z: 4.30

NBIS

Hold

47

out of 100

Grade: D+

Growth: 6.7Profit: 4.0Value: 4.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CAHUndervalued (+14.8%)

Margin of Safety

+14.8%

Fair Value

$263.37

Current Price

$211.31

$52.06 discount

UndervaluedFair: $263.37Overvalued
NBISSignificantly Overvalued (-11714.7%)

Margin of Safety

-11714.7%

Fair Value

$0.75

Current Price

$115.09

$114.34 premium

UndervaluedFair: $0.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAH2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.3010/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

NBIS1 strengths · Avg: 8.0/10
PEG RatioValuation
0.638/10

Growing faster than its price suggests

Areas to Watch

CAH4 concerns · Avg: 3.3/10
P/E RatioValuation
29.8x4/10

Moderate valuation

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.7%3/10

0.7% margin — thin

Operating MarginProfitability
1.2%3/10

Operating margin of 1.2%

NBIS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.7%3/10

ROE of 0.7% — below average capital efficiency

Debt/EquityHealth
1.063/10

Elevated debt levels

P/E RatioValuation
1044.6x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CAH

The strongest argument for CAH centers on Altman Z-Score, Revenue Growth. Revenue growth of 18.8% demonstrates continued momentum. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bull Case : NBIS

The strongest argument for NBIS centers on PEG Ratio. Profitability is solid with margins at 19.2% and operating margin at -103.0%. PEG of 0.63 suggests the stock is reasonably priced for its growth.

Bear Case : CAH

The primary concerns for CAH are P/E Ratio, Return on Equity, Profit Margin. Thin 0.7% margins leave little buffer for downturns.

Bear Case : NBIS

The primary concerns for NBIS are EPS Growth, Return on Equity, Debt/Equity. A P/E of 1044.6x leaves little room for execution misses.

Key Dynamics to Monitor

CAH profiles as a growth stock while NBIS is a mature play — different risk/reward profiles.

NBIS carries more volatility with a beta of 1.16 — expect wider price swings.

CAH is growing revenue faster at 18.8% — sustainability is the question.

CAH generates stronger free cash flow (555M), providing more financial flexibility.

Bottom Line

CAH scores higher overall (53/100 vs 47/100) and 18.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardinal Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cardinal Health, Inc. is an American multinational health care services company.

Visit Website →

Nebius Group N.V.

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Nebius Group N.V. (Ticker: NBIS) is an innovative technology firm focused on delivering advanced digital solutions that enhance client engagement and operational efficiency across various industries. Leveraging cutting-edge technologies such as cloud computing, artificial intelligence, and data analytics, Nebius empowers businesses to effectively navigate the complexities of the digital landscape. With a robust portfolio of intellectual property and strategic partnerships, the company is well-positioned to capitalize on growth opportunities in the rapidly evolving tech sector, making it an attractive investment for institutional investors aiming to access high-growth potential in technology-driven markets.

Visit Website →

Want to dig deeper into these stocks?